Cargando…

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin

We conducted a phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Fostriecin was administered intravenously over 60 min on days 1–5 at 4-week intervals. Dose was escalated from 2 mg m(−2)day(−1)to 20 mg m(−2)day(−1)in 20 patients. Drug pharmacokinetics was anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jong, R S de, Mulder, N H, Uges, D R A, Sleijfer, D Th, Höppener, F J P, Groen, H J M, Willemse, P H B, Graaf, W T A van der, Vries, E G E de
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362650/ https://www.ncbi.nlm.nih.gov/pubmed/10070885 http://dx.doi.org/10.1038/sj.bjc.6690141

Ejemplares similares

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
por: Mulder, P. O., et al.
Publicado: (1990)

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
por: Gietema, J. A., et al.
Publicado: (1995)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
por: Gietema, J. A., et al.
Publicado: (1993)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
por: Withoff, S., et al.
Publicado: (1996)

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.
por: Groen, H. J., et al.
Publicado: (1995)

Cisplatin in breast cancer.
por: Willemse, P., et al.
Publicado: (1993)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
por: de Graaf, H., et al.
Publicado: (1997)

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
por: de Vries, E. G., et al.
Publicado: (1993)

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.
por: Sleijfer, S., et al.
Publicado: (1996)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1990)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours
por: Paridaens, R, et al.
Publicado: (2000)

Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases
por: Kruczynski, A, et al.
Publicado: (2000)

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
por: van Putten, J W G, et al.
Publicado: (2000)

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
por: Twelves, C J, et al.
Publicado: (1999)

Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases
por: Barret, J-M, et al.
Publicado: (2000)

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.
por: Guchelaar, H. J., et al.
Publicado: (1992)

Geographic clustering of testicular cancer incidence in the northern part of The Netherlands
por: Sonneveld, D J A, et al.
Publicado: (1999)

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
por: Biesma, B., et al.
Publicado: (1992)

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
por: de Jong, R. S., et al.
Publicado: (1997)

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β
por: Zhou, Z, et al.
Publicado: (2001)

Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
por: Lage, H, et al.
Publicado: (2000)

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
por: Meijer, C., et al.
Publicado: (1990)

Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells
por: Barthelmes, H U, et al.
Publicado: (2001)

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism
por: Maring, Jan Gerard, et al.
Publicado: (2010)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
por: Guichard, S, et al.
Publicado: (1999)

Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
por: Groen, H. J., et al.
Publicado: (1995)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation
por: Schröder, C P, et al.
Publicado: (2001)

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
por: Bowman, K J, et al.
Publicado: (2001)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
por: Maring, J G, et al.
Publicado: (2002)

Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.
por: Sark, M. W., et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_losclkpqo4fihfiq65ba7d8flg